Trial Profile

A phase 2/3 study of Rupitasertib in refractory ER+ HER2- metastatic breast cancer

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rupitasertib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

09 Jan 2024 New trial record
04 Jan 2024 According to an Evexta Bio media release, rupitasertib, is expected to enter a phase 2/3 clinical trial in refractory ER+ HER2 metastatic breast cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com